European Pharmaceutical Review

AUGUST 21, 2023

billion by 2030 and grow at a CAGR of 3.84 percent from 2023 to 2030. The data stated that expansion of the market in emerging countries is due to factors such as the rising success rate of RNA-based COVID-19 vaccines, regulatory approval, as well as demand for personalised medicines.

Vaccines 98

Vaccines 98

Express Pharma

DECEMBER 11, 2024

billion in 2030, with the pediatric and adult segments accounting for $2.2 Six more products in late-stage development have potential to launch by 2030. Various unmet needs are expected to be addressed over the forecast period, including more prophylactic options across the different patient segments, as well as combination vaccines.

Vaccines 66

Vaccines Compounding 66

The Guardian - Pharmaceutical Industry

APRIL 7, 2023

Exclusive: Pharmaceutical firm says groundbreaking jabs could save millions of lives ‘A silver lining’: how Covid ushered in a vaccines golden era Millions of lives could be saved by a groundbreaking set of new vaccines for a range of conditions including cancer, experts have said.

Vaccines 111

Vaccines 111

Express Pharma

JANUARY 22, 2024

Cameroon has kickstarted the world’s first routine vaccine programme against malaria. It is one of 20 African countries planning to introduce the drug this year, according to global vaccine alliance Gavi. The vaccine is designed to be administered to young children in four doses from around five months of age.

Vaccines 105

Vaccines 105

Express Pharma

AUGUST 27, 2024

Bharat Biotech (BBIL) has launched HILLCHOL (BBV131), an oral cholera vaccine developed under license from Hilleman Laboratories. To meet global demand, Bharat Biotech has established large-scale manufacturing facilities in Hyderabad and Bhubaneswar with a capacity to produce up to 200 million doses of the vaccine annually.

Vaccines 111

Vaccines 111

Express Pharma

DECEMBER 18, 2024

Additionally, the industry is set to make notable progress in cutting-edge areas such as CAR-T cell therapy, mRNA vaccines, and the development of complex molecules, which hold immense potential for driving future growth. Indian pharma market is expected to move up to USD 120-130 Billion by 2030 from current size of USD 58 Billion.

Biosimilars 78

Biosimilars Vaccines 78

European Pharmaceutical Review

OCTOBER 4, 2023

The World Health Organization ( WHO ) has recommended a new vaccine, R21/Matrix-M, to prevent malaria in children. The R21 vaccine is the second malaria vaccine recommended by WHO. This follows the WHO’s recommendation of the RTS,S/AS01 vaccine for the disease in 2021.

Vaccines 111

Vaccines 111

Express Pharma

OCTOBER 16, 2024

Messenger ribonucleic acid (mRNA)-based innovator pharmaceuticals saw a staggering 800 per cent increase in licensing agreement deal values from 2019 to 2024YTD, driven by the remarkable success of mRNA vaccines during the COVID-19 pandemic. billion in 2030. Bristol Myers Squibb formed a multi-year, $1.87

Vaccines 104

Vaccines Immunity Immunization Diabetes 104

European Pharmaceutical Review

NOVEMBER 18, 2022

The World Health Organization (WHO)’s Global Vaccine Market Report 2022 , the first report to examine the impact of COVID-19 on the global vaccine market, shows that inequitable distribution is not unique to COVID-19 vaccines, with poorer countries consistently fighting to access vaccines in demand by wealthier countries.

Vaccines 98

Vaccines Immunity Immunization Documentation 98

European Pharmaceutical Review

JULY 12, 2023

The first conjugate vaccine to protect against the five predominant causes of meningococcal meningitis in Africa, has been prequalified by the World Health Organization (WHO). MenFive ® has been developed through a 13-year collaboration between the world’s largest vaccine manufacturer Serum Institute of India Pvt.

Vaccines 98

Vaccines Immunity Immunization 98

European Pharmaceutical Review

DECEMBER 2, 2022

Vaccines Europe has unveiled its first pipeline review of its 15 members companies, with 100 vaccine candidates as of July 2022. . The data indicated 46 percent of the vaccine candidates target infections that do not have an available vaccine. Establish digital vaccination registries to improve vaccination coverage rates.

Vaccines 98

Vaccines Immunity Immunization 98

STAT

DECEMBER 13, 2024

Specifically, the amount spent on basic research, new treatments, vaccines, and diagnostics was $1.2 Yet this amounted to only one quarter of the $5 billion annual goal that was adopted last year at a United Nations High-Level Meeting on TB as part of a plan to end the epidemic by 2030. Meanwhile, the U.S.

Pharmaceutical Companies 141

Pharmaceutical Companies Pharmaceutical Companies Vaccines Drug Pricing 141

Pharmaceutical Technology

SEPTEMBER 22, 2022

It is the year 2030. It could be that you are lucky, and there is already a cancer vaccine on the market that you will get priority for. Alternatively, there are vaccines ready to enter decentralised third-phase clinical trials, so you can enrol quickly. It is the year 2030.

Vaccines 137

Vaccines Hospitals 137

Pharmaceutical Technology

MAY 25, 2023

A new vaccine developed by the Serum Institute of India to fight meningococcal disease could help eliminate meningitis across Africa. The results from a trial, published in The New England Journal of Medicine , found the vaccine was associated with a strong immune response and good safety profile. percentage points (96% CI, −0.3

Vaccines 78

Vaccines Immunity Immunization 78

Pharma Mirror

OCTOBER 28, 2021

Amsterdam, The second part of the 2021 CPhI Annual Report looks ahead to predict the pharma manufacturing, therapeutic and technology environment in 2030. The post CPhI Annual Report 2021: Short term reshoring the catalyst for longer term manufacturing innovations by 2030 appeared first on Pharma Mirror Magazine.

Vaccines 52

Vaccines 52

Express Pharma

SEPTEMBER 20, 2023

The free vaccination camps will be run with support of Brihanmumbai Municipal Corporation (BMC). The ‘Stop Rabies’ initiative aligns with India’s National Action Plan for Dog-Mediated Rabies Elimination by 2030. It adopts a two-pronged approach of vaccination and education.

Vaccines 104

Vaccines 104

Express Pharma

JANUARY 12, 2024

With the Indian Pharma sector trying to reach the USD 130 Billion target by 2030, there is a renewed spirit of research in the areas of cell and gene therapy, biologics and biosimilars apart from the already strong generic and vaccine manufacturing sectors of the country.

Biosimilars 105

Biosimilars Vaccines 105

pharmaphorum

JANUARY 6, 2023

The UK has formed an partnership with German biotech BioNTech to provide up to 10,000 patients with access to personalised cancer therapies, in another example of the country embracing the mRNA technologies that underpinned COVID-19 vaccines. It will also cover some infectious disease targets.

Vaccines 111

Vaccines Immunity Immunization Drug Development 111

European Pharmaceutical Review

JUNE 27, 2022

The Kigali Summit on Malaria and NTDs , hosted by His Excellency (HE) Paul Kagame, President of the Republic of Rwanda, on Thursday 23 June 2022, gathered world leaders to commit to ending these devastating diseases by the end of 2030. These hubs have more than 30 potential vaccines and medicines targeting 13 high-burden infectious diseases.

Vaccines 110

Vaccines Communication Documentation Compounding 110

Express Pharma

DECEMBER 20, 2024

Renowned for its extensive production of generic drugs and vaccines, the sector has played a pivotal role in addressing global healthcare demands. As of 2024, India has produced nearly half of the eight billion vaccine doses distributed worldwide, cementing its reputation as a reliable healthcare contributor.

Biosimilars 101

Biosimilars Vaccines 101

European Pharmaceutical Review

SEPTEMBER 1, 2023

billion by 2030 BioNTech Development of mRNA-based oncology therapies for German biotech BioNTech is progressing. BioNTech to support trial access for cancer immunotherapies Developing an mRNA cancer vaccine In terms of disease indication, melanoma remains the primary focus of advanced mRNA-based therapies, GlobalData reported.

Immunity 110

Immunity Immunization Vaccines 110

European Pharmaceutical Review

JULY 6, 2023

BioNTech SE and the UK government have jointly agreed to provide up to 10,000 patients with personalised cancer immunotherapies by 2030. If successfully developed, this means cancer vaccines could become part of standard care. Signing of this agreement builds on a memorandum of understanding signed in January.

Vaccines 98

Vaccines 98

pharmaphorum

JANUARY 10, 2023

Since then, the two partners have developed multiple AI-based applications including a platform for selecting neoantigens for use in individualised cancer vaccines and an early warning system for high risk SARS-CoV-2 variants based on how well they can evade the immune system and their transmissibility. link] pic.twitter.com/XHh0Y009fK.

Immunity 116

Immunity Immunization Vaccines 116

pharmaphorum

MAY 9, 2022

Johnson & Johnson has halved the size of its collaboration with Bavarian Nordic on vaccine development, jettisoning its stake in shots targeting human papillomavirus (HPV) and hepatitis B virus (HBV). The aim of both alliances was to study MVA-BN in a prime-boost vaccine regimen with Janssen’s own AdVac vaccine technology.

Vaccines 52

Vaccines 52

European Pharmaceutical Review

NOVEMBER 7, 2024

percent between 2025 and 2030. Increasing demand for biopharmaceuticals, “including therapeutic proteins and vaccines, drives the use of rocking bioreactors in cell culture processes”, the reported explained. Key companies profiled in the single-use technology rocking bioreactor market report included Thermo Fisher Scientific Inc.,

Compounding 52

Compounding Vaccines 52

Express Pharma

MARCH 20, 2023

India is preparing to include human papillomavirus (HPV) vaccines as part of the government-driven public immunization program popularly known as the Universal Immunization Program (UIP). The Indian government will float a global tender in April 2023 to procure HPV vaccines. million in 2030. million in 2030.

Vaccines 52

Vaccines Immunity Immunization 52

pharmaphorum

JUNE 1, 2022

Practical examples of this include healthcare professionals using VR to learn various medical procedures or for the technology to be used to teach broader society about public health issues, such as the importance of vaccination. When both ‘treatments’ were combined, the vaccination intention increased even further. The more you know.

Vaccines 145

Vaccines Immunity Immunization Hospitals 145

Express Pharma

JANUARY 4, 2024

The Indian pharma industry is on a solid growth trajectory, surging from $40 billion in 2021 to an estimated $130 billion in 2030, with a steady double-digit CAGR for the next 10 years. It meets 50 per cent of the global demand for various vaccines, 40 per cent of the generic demand in the US, and 25 per cent of all medicine in the UK.

Packaging 111

Packaging Labelling Vaccines 111

European Pharmaceutical Review

NOVEMBER 13, 2024

Lenacapavir for PrEP could provide an important alternative to existing preventative medications that require more frequent dosing, and could help transform the HIV prevention landscape by addressing a range of unmet needs for individuals who need or want PrEP globally,” Ogbuagu added.

Vaccines 96

Vaccines 96

Express Pharma

NOVEMBER 26, 2024

With the Indian pharma market projected to grow to $ 130 billion by 2030 and $ 450 billion by 2047, the event highlighted the industry’s vital role in shaping global healthcare. Projections indicate exports will soar to $130 billion by 2030 and $450 billion by 2047. With exports nearing $27.84 trillion.

Packaging 105

Packaging Biosimilars Pharmaceutical Manufacturing Dosage 105

pharmaphorum

AUGUST 3, 2022

The fall reflects “COVID-19 related rates and severity of infections and hospitalisations, as well as the availability, uptake and effectiveness of vaccinations and alternative treatments for COVID-19,” said the company.

Vaccines 105

Vaccines 105

European Pharmaceutical Review

JANUARY 6, 2023

BioNTech has signed an agreement with the UK Government to help accelerate clinical trials for personalised mRNA immunotherapies, with the aim to provide personalised cancer therapies for up to 10,000 patients by the end of 2030. Infectious disease vaccines. The collaboration will focus on three strategic pillars.

Vaccines 52

Vaccines 52

European Pharmaceutical Review

SEPTEMBER 7, 2022

billion market by 2030, growing from a 2020 value of around $2.4 New types of drugs, such as oral vaccines, will also be formulated as capsules. Insights on the Empty Capsules Global Market to 2030 – Featuring ACG Worldwide, Bright Pharma Caps and Lonza Among Others [Internet]. About the author. GlobeNewswire News Room.

Dosage 124

Dosage Vaccines Diabetes 124

European Pharmaceutical Review

JANUARY 22, 2024

million by 2030, according to a report by ResearchAndMarkets. Between 2023 to 2030, this represents a CAGR of 15.13 As the expansion of the biopharmaceutical industry has continued, in 2022, increased demand for vaccine production enabled the Asia Pacific region to witness “significant growth”, with a CAGR of 15.32

Vaccines 52

Vaccines 52

pharmaphorum

NOVEMBER 6, 2022

The new drug will reach the market ahead of RSV vaccines that are designed to protect newborns in the months after birth by vaccinating expectant mothers, who pass on antibodies against the virus in the womb. AZ and Sanofi say they hope to launch the antibody next autumn, in time for the 2023/24 RSV season.

Vaccines 64

Vaccines Labelling 64

Pharmaceutical Technology

JUNE 27, 2022

The international agency had previously set a target of eliminating viral hepatitis by 2030. As such, a hepatitis C vaccine may yet be needed for elimination, since there are cohorts of patients who will not be reached, Foster said during the subsequent panel discussion.

Vaccines 105

Vaccines 105

Express Pharma

NOVEMBER 24, 2023

With objectives laid down during the G20 presidency, the industry in India is poised to scale to $65 billion by 2024 and surpass $130 billion by 2030, driven by heightened pharma innovation, technological advancements, and a focus on breakthrough products.

Packaging 105

Packaging Vaccines Pharmaceutical Manufacturing Hospitals 105